GOHEALTHCARE SPECIALTY REVENUE CYCLE MANAGEMENT

Revenue Integrity & Compliance for Orthobiologics & Regenerative MSK Medicine

Q: What should A/R follow-up show for Orthobiologics & Regenerative MSK Medicine?

Each material balance should have a reason, owner, next action and deadline. Repeated balances with the same cause should trigger upstream corrective action.

Revenue Integrity & Compliance for Orthobiologics & Regenerative MSK Medicine: specialty-specific payer workflows, reimbursement, denials, compliance, coding, A/R and revenue protection from GoHealthcare Practice Solutions.

Developed by GoHealthcare Practice Solutions
Expert Review: Pinky Maniri, MSc
CRCR, CSAPM, CSPPM, CSBI, CSPR, CSAF
Certified in Healthcare A.I. Governance
CEO & Founder

Request an RCM Assessment View Orthobiologics & Regenerative MSK Medicine RCM

REVENUE INTEGRITY & COMPLIANCE

Revenue integrity protects both sides of the equation: it finds revenue legitimately earned but missed, and it prevents reimbursement that is not supported. That is why coding, authorization, documentation, charge capture, contracts, overpayments and compliance belong in one control framework.

SPECIALTY CONTEXT

Orthobiologics RCM begins with a question that traditional billing teams often skip: is the service covered at all? Evidence status, FDA/regulatory status, payer medical policy, coding and patient financial responsibility are separate issues and must be resolved before treatment.

REFERENCE YEAR

2026. Verify current payer policies, code sets, contracts, fee schedules, NCCI/MUE edits and jurisdiction-specific requirements.

Operational use: Built for physicians, executives, administrators, RCM leaders, prior authorization teams, coders, compliance professionals and specialty operations teams. The objective is compliant reimbursement performance, not aggressive billing.

DIRECT ANSWER

Revenue Integrity & Compliance

Orthobiologics & Regenerative MSK Medicine revenue integrity and compliance should be managed from the final clinical service backward to the financial requirements that govern it. The practical test is whether eligibility, authorization, documentation, coding, claim data and payment expectations still agree when the service is ready to bill.

PRACTICAL RCM POINT

In Orthobiologics & Regenerative MSK Medicine, the payer response is often where an earlier defect becomes visible. RCM leadership should identify the first failed handoff, resolve the account and then correct the upstream process.

SPECIALTY REALITY

Where Orthobiologics & Regenerative MSK Medicine Revenue Integrity And Compliance Breaks Down

In Orthobiologics & Regenerative MSK Medicine, revenue integrity and compliance problems rarely stay in one department. A scheduling assumption can become an authorization mismatch; an authorization mismatch can become a coding or claim defect; and a payment issue can sit in A/R unless the original cause is visible.

Specialty Revenue Challenge	Why It Matters	Operational Control
Teams start with prior authorization instead of benefit status	A payer may classify the therapy as excluded or investigational, making standard PA an incomplete workflow.	Perform benefit and medical-policy investigation first.
Different biologic products are called the same thing	PRP, BMAC, cell/tissue products, amniotic products, exosomes and prolotherapy have different regulatory and coverage issues.	Identify the exact product/procedure before coding or financial communication.
A code is mistaken for coverage	The existence of a CPT/HCPCS or unlisted pathway does not make a therapy payable.	Separate coding availability from benefit coverage.
Self-pay is used without enough financial disclosure	Patients may believe insurance refusal is temporary or appealable when the plan has a clear exclusion.	Document the reason for noncoverage and patient financial responsibility.
Marketing claims create compliance exposure	Aggressive claims about regeneration or FDA status can contradict evidence/regulatory reality.	Audit website, consent and sales language.
PRP is frequently miscoded as a conventional injection	This can bypass payer policy and create false-claim risk.	Use accurate code/reporting pathway.
Product cost is not tied to refund/collection policy	High-cost products can create disputes when treatment is cancelled or denied.	Establish written financial and inventory controls.
Appeals target the wrong issue	A medical-necessity letter cannot necessarily overcome a contractual exclusion.	Classify denial as exclusion, investigational policy, medical necessity, coding or administrative defect.

Teams start with prior authorization instead of benefit status

A payer may classify the therapy as excluded or investigational, making standard PA an incomplete workflow. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Perform benefit and medical-policy investigation first. For Revenue Integrity & Compliance, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

Different biologic products are called the same thing

PRP, BMAC, cell/tissue products, amniotic products, exosomes and prolotherapy have different regulatory and coverage issues. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Identify the exact product/procedure before coding or financial communication. For Revenue Integrity & Compliance, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

A code is mistaken for coverage

The existence of a CPT/HCPCS or unlisted pathway does not make a therapy payable. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Separate coding availability from benefit coverage. For Revenue Integrity & Compliance, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

Self-pay is used without enough financial disclosure

Patients may believe insurance refusal is temporary or appealable when the plan has a clear exclusion. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Document the reason for noncoverage and patient financial responsibility. For Revenue Integrity & Compliance, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

Marketing claims create compliance exposure

Aggressive claims about regeneration or FDA status can contradict evidence/regulatory reality. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Audit website, consent and sales language. For Revenue Integrity & Compliance, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

PRP is frequently miscoded as a conventional injection

This can bypass payer policy and create false-claim risk. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Use accurate code/reporting pathway. For Revenue Integrity & Compliance, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

Product cost is not tied to refund/collection policy

High-cost products can create disputes when treatment is cancelled or denied. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Establish written financial and inventory controls. For Revenue Integrity & Compliance, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

Appeals target the wrong issue

A medical-necessity letter cannot necessarily overcome a contractual exclusion. In a Orthobiologics & Regenerative MSK Medicine revenue cycle, that problem rarely stays in one department. It can move from scheduling to authorization, from documentation to coding, from coding to claim edits, and then into A/R or an appeal. By the time the payer denies the claim, the original defect may be weeks or months old.

Classify denial as exclusion, investigational policy, medical necessity, coding or administrative defect. For Revenue Integrity & Compliance, the control should be measurable. Leadership should be able to identify who owns it, which data proves it was completed, how exceptions are escalated and whether the same defect appears again in denial or underpayment data.

SERVICE LINE

High-Value Services and Revenue Exposure

Specialty Service / Revenue Category	Primary Revenue-Cycle Risk	Core Control
PRP	Benefit policy and accurate Category III reporting.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
BMAC	Product/processing identification and payer policy.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Amniotic/placental products	Noncoverage/regulatory review.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Cellular therapies	FDA/payer policy and self-pay controls.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Exosome products	High regulatory and coverage caution.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Prolotherapy	Distinct evidence/coverage pathway.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Autologous protein solutions	Product-specific policy.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Surgical biologic augmentation	Primary surgery authorization does not guarantee biologic payment.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Cartilage/bone-healing adjuncts	Outcome and payer policy vary.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.
Spine/intradiscal regenerative services	Highly restrictive coverage and unlisted coding risk.	Before billing, reconcile the clinical service, authorization/benefit status, documentation, code family, units/modifiers where applicable, site of service and expected payer treatment.

PRP

Benefit policy and accurate Category III reporting. The revenue integrity & compliance workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

BMAC

Product/processing identification and payer policy. The revenue integrity & compliance workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

Amniotic/placental products

Noncoverage/regulatory review. The revenue integrity & compliance workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

Cellular therapies

FDA/payer policy and self-pay controls. The revenue integrity & compliance workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

Exosome products

High regulatory and coverage caution. The revenue integrity & compliance workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

Prolotherapy

Distinct evidence/coverage pathway. The revenue integrity & compliance workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

Autologous protein solutions

Product-specific policy. The revenue integrity & compliance workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

Surgical biologic augmentation

Primary surgery authorization does not guarantee biologic payment. The revenue integrity & compliance workflow should start before the claim. Verify the clinical service actually planned, benefit/authorization status, documentation requirements, code family, site of service and payer-specific payment treatment. Once the service is furnished, the final record must be reconciled back to what was scheduled and authorized.

LEAKAGE MATRIX

Revenue Leakage vs Compliance Exposure

Scenario	Revenue Risk	Compliance Risk
Missed supported charge	Underpayment/leakage	Low if corrected accurately.
Unsupported charge	Temporary overstatement	High.
Wrong modifier	Denial or excess payment	Potential high risk.
Authorization mismatch	Denial	Medical-necessity/claim accuracy concerns.
Contract underpayment	Lost revenue	Low if recovery is accurate.
Overpayment retained	False financial performance	High.
Duplicate claim	A/R confusion	Potential overpayment risk.
Incorrect patient balance	Lost trust/collections issue	Consumer/compliance risk.

OIG FRAMEWORK

Compliance Program Elements Inside RCM

RCM should support written policies, accountable compliance leadership, training, communication, auditing/monitoring, response/corrective action and consistent enforcement. Revenue-cycle findings should feed the organization's compliance program rather than remain isolated billing issues.

REVENUE INTEGRITY

Where Revenue Is Won or Lost

For Orthobiologics & Regenerative MSK Medicine, the financial result is created across connected decisions rather than at claim submission alone. Eligibility and benefits, authorization, the final record, coding, charge capture, claim routing, adjudication and follow-up all have to tell the same story.

A useful control identifies the first point where the Orthobiologics & Regenerative MSK Medicine case stopped matching the payer, coding or payment requirement and fixes that point before the same defect repeats.

Control Point	What Must Be True
Patient access	Correct patient, payer, product, network and coordination-of-benefits information.
Authorization	The approval/benefit determination matches the actual service, provider, site, anatomy, units and dates where required.
Documentation	The medical record supports what was clinically performed and why.
Coding	Codes, modifiers and units accurately represent the documented work.
Claim	Correct entity, POS, payer route and required supporting data.
Payment	Remittance is compared with contract/fee schedule and expected allowed amount.
A/R	Every open balance has a reason, owner, next action and deadline.
Compliance	Unsupported payment is not pursued or retained.

DENIAL INTELLIGENCE

Denial Patterns That Deserve Root-Cause Review

Denial / Payment Failure	Typical Cause	Resolution Principle
Experimental/investigational	Policy excludes or noncovers service.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.
Benefit exclusion	Contract does not include therapy.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.
Wrong code	Conventional injection code used for regenerative service.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.
Product not covered	Payer does not reimburse product separately.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.
No authorization	Plan requires review even when coverage is uncertain.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.
Medical necessity	Patient-specific evidence does not meet plan threshold.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.
Claim edit/unlisted processing	Payer requires records/manual review.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.
Patient dispute/refund	Financial disclosure was unclear.	Identify the actual root cause first. Correct the workflow defect when possible; appeal only when the policy, contract and patient-specific record support an appeal.

Experimental/investigational

Resolve the denial according to the actual cause in the Orthobiologics & Regenerative MSK Medicine account. A correctable claim defect, medical-necessity decision, authorization problem and contractual payment variance are different problems and should not share one appeal workflow.

When the same Orthobiologics & Regenerative MSK Medicine denial pattern repeats, track it back to the upstream step that created it. Reworking the same category in A/R is not a durable control.

Benefit exclusion

Contract does not include therapy.

Wrong code

Conventional injection code used for regenerative service.

Product not covered

Payer does not reimburse product separately.

No authorization

Plan requires review even when coverage is uncertain.

Medical necessity

Patient-specific evidence does not meet plan threshold.

Claim edit/unlisted processing

Payer requires records/manual review.

Patient dispute/refund

Financial disclosure was unclear.

COMPLIANCE

Compliance and Revenue Integrity

Revenue integrity in Orthobiologics & Regenerative MSK Medicine means capturing supported services accurately while stopping unsupported billing, incorrect patient responsibility and overpayments. Documentation and coding should reflect the care actually furnished; financial pressure should never create the clinical facts.

Do not code a noncovered regenerative service as a conventional covered injection.
Do not state a product is FDA approved unless that specific status is accurate.
Do not imply self-pay status means the treatment is proven.
Do not alter diagnosis to fit a policy.
Document product source/processing as appropriate.
Provide clear informed financial disclosure.
Monitor vendor marketing and inducement risk.
Investigate and return any overpayment caused by incorrect coding.

COMPLIANCE POINT

For Orthobiologics & Regenerative MSK Medicine, a payment strategy is not defensible if it requires coding that is less accurate than the clinical record.

REIMBURSEMENT

Where Legitimate Reimbursement Is Lost

For Orthobiologics & Regenerative MSK Medicine, reimbursement improves when the organization prevents avoidable defects, captures supported charges, reconciles actual payment to the governing methodology and resolves high-value balances before they age. The objective is accurate payment for documented care—not more billable lines.

Compliant reimbursement improvement in Orthobiologics & Regenerative MSK Medicine means preventing avoidable denials, capturing supported charges, maintaining accurate documentation and coding, identifying payer underpayments and resolving high-value balances before the same defect repeats.

1. Perform benefit investigation before scheduling.

2. Maintain a product-specific policy matrix.

3. Use transparent self-pay financial workflows.

4. Audit all regenerative medicine marketing claims.

5. Create accurate coding pathways for PRP/unlisted services.

6. Track denials by exclusion vs investigational vs administrative cause.

7. Measure product cost, collection and refund exposure.

8. Keep outcome tracking to support evidence and patient communication.

9. Separate covered primary surgery from noncovered biologic adjunct.

10. Route regulatory questions to qualified compliance/legal/regulatory review.

KPI

KPIs Worth Watching

KPI	Management Use
Benefit-verification completeness	Before scheduling.
Policy classification	Covered/excluded/investigational.
Self-pay collection accuracy	Quoted vs collected.
Refund/dispute rate	Financial clarity.
Coding exception rate	Unlisted/manual claims.
Denial mix	Policy vs administrative.
Product margin	After refunds/collection cost.
Outcome capture	PROM/safety follow-up.

Measure Orthobiologics & Regenerative MSK Medicine performance by payer, location, provider and service family so the dashboard shows where the defect is occurring. Define each metric consistently before comparing trends or setting targets.

AUDIT

What to Audit First

Use a risk-based Orthobiologics & Regenerative MSK Medicine audit sample rather than random claims. Prioritize high-value services, high-denial payers, recurring documentation or modifier issues, aged balances, unlisted-code use and large payment variances.

Audit Test 1

Take one high-value Orthobiologics & Regenerative MSK Medicine account and trace it from scheduling through final payment. Identify the first point where the case, authorization, record, code set, claim or remittance stopped matching the expected result.

Audit Test 2

Audit Test 3

Audit Test 4

Audit Test 5

Audit Test 6

Audit Test 7

Audit Test 8

COMMON QUESTIONS

Frequently Asked Questions

What is the main revenue-cycle risk in Orthobiologics & Regenerative MSK Medicine revenue integrity and compliance?

What should be verified before a Orthobiologics & Regenerative MSK Medicine claim is released?

How should Orthobiologics & Regenerative MSK Medicine denials be worked?

How should documentation and coding be reconciled in Orthobiologics & Regenerative MSK Medicine?

What should A/R follow-up show for Orthobiologics & Regenerative MSK Medicine?

Each material Orthobiologics & Regenerative MSK Medicine balance should have a reason, owner, next action and deadline. Repeated balances with the same cause should trigger upstream corrective action.

Which Orthobiologics & Regenerative MSK Medicine RCM metrics are most useful?

RELATED RESOURCES

Related GoHealthcare Specialty RCM Pages

GoHealthcare Resource	How It Connects	URL
Revenue Cycle Management	Primary GoHealthcare RCM flagship page.	https://www.gohealthcarellc.com/revenue-cycle-management.html
RCM Services for Orthobiologics & Regenerative MSK Medicine	Specialty RCM hub.	https://www.gohealthcarellc.com/rcm-services-orthobiologics-regenerative-msk-medicine.html
Full-Service RCM	Core managed RCM service.	https://www.gohealthcarellc.com/rcm-full-services.html
RCM Process	End-to-end operating workflow.	https://www.gohealthcarellc.com/revenue-cycle-management-process.html
Revenue Integrity	Revenue leakage, coding and compliance.	https://www.gohealthcarellc.com/revenue-integrity-msk-specialty-care.html
Prior Authorization Resource Center	Pre-service payer and medical-necessity operations.	https://www.gohealthcarellc.com/overview.html
Procedure Library	Procedure-specific clinical, coding and payer intelligence.	https://www.gohealthcarellc.com/procedure-library.html
Orthobiologics & Regenerative MSK Medicine Specialty Guide	Clinical and specialty operations reference.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-medicine-specialty-hub.html
Medical Billing Services	Related specialty RCM authority page.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-medical-billing-services.html
Medical Coding & Documentation	Related specialty RCM authority page.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-medical-coding-documentation.html
Prior Authorization & Revenue Protection	Related specialty RCM authority page.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-prior-authorization-revenue-protection.html
Denial Management & Appeals	Related specialty RCM authority page.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-denial-management-appeals.html
A/R & Underpayment Recovery	Related specialty RCM authority page.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-accounts-receivable-underpayment-recovery.html
Revenue Integrity & Compliance	Related specialty RCM authority page.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-revenue-integrity-compliance.html
Reimbursement Optimization & RCM KPIs	Related specialty RCM authority page.	https://www.gohealthcarellc.com/orthobiologics-regenerative-msk-reimbursement-optimization-rcm-kpis.html

REFERENCES

Authoritative References

Authority	Reference
Primary / Specialty Source	May 2026 Regenerative Medicine Warning https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/patient-and-consumer-warning-about-potential-serious-risks-harm-following-use-unapproved-products
Primary / Specialty Source	PRP MSK LCD example https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39058
Primary / Specialty Source	Amniotic/Placental MSK LCD example https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=39879&ver=10
Primary / Specialty Source	General Compliance Program Guidance https://oig.hhs.gov/compliance/general-compliance-program-guidance/
Primary / Specialty Source	2026 Medicare Physician Fee Schedule https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare-physician-fee-schedule-final-rule-cms-1832-f
Primary / Specialty Source	2026 NCCI Policy Manual https://www.cms.gov/medicare/coding-billing/national-correct-coding-initiative-ncci-edits/medicare-ncci-policy-manual
Primary / Specialty Source	CPT Licensing https://www.ama-assn.org/practice-management/cpt/cpt-licensing
Official Source	CMS MUE Program https://www.cms.gov/medicare/coding-billing/national-correct-coding-initiative-ncci-edits/medicare-ncci-medically-unlikely-edits-mues

Find the revenue-cycle defects before they become aged A/R.

GoHealthcare can assess Orthobiologics & Regenerative MSK Medicine workflows across patient access, prior authorization, documentation, coding, claims, denials, A/R, underpayments and revenue integrity.

Request an RCM Assessment Return to Specialty RCM Hub

GOHEALTHCARE RCM AUTHORITY CENTER

Explore All 150 RCM Authority Pages

Move across the complete GoHealthcare MSK and Injury Revenue Cycle Management knowledge system: specialty RCM, medical billing and coding, coverage and reimbursement intelligence, injury cases, workers’ compensation, in-network and out-of-network RCM, and ancillary MSK services.

Revenue Cycle Management — Main Flagship Page

Ambulatory Surgery Centers

Hand & Upper Extremity

Interventional Pain Management

MSK Radiology & Diagnostic Imaging

Neuromodulation

Neurosurgery

Occupational Medicine / Workers’ Compensation MSK

Orthobiologics & Regenerative MSK Medicine

Orthopedic Surgery

Physical Medicine & Rehabilitation (PM&R)

Spine & Interventional Spine

Sports Medicine

Medical Billing, Coding & Reimbursement Intelligence

Injury Case RCM

In-Network & Out-of-Network RCM

Ancillary MSK RCM

ABOUT THE EXPERT REVIEWER

Pinky Maniri, MSc

CRCR, CSAPM, CSPPM, CSBI, CSPR, CSAF
Certified in Healthcare A.I. Governance
CEO & Founder, GoHealthcare Practice Solutions

Pinky Maniri is a healthcare operations and financial management executive with approximately 30 years of experience in revenue cycle management, prior authorization, payment and reimbursement, physician and ambulatory practice operations, healthcare finance, business intelligence, and MSK specialty healthcare operations.

HFMA Certified Professional in:

Physician Practice Management
Ambulatory Practice Management
Revenue Cycle Management
Payment & Reimbursement
Accounting & Finance
Business Intelligence
Healthcare A.I. Governance

Editorial Review Scope

This resource was developed by GoHealthcare Practice Solutions and reviewed for healthcare operations, revenue cycle, reimbursement, and operational accuracy. Coverage, coding, medical necessity, utilization management, payer policy, and reimbursement requirements may vary by payer, plan, jurisdiction, setting, and date of service. Current authoritative sources should be reviewed before applying information to a specific patient, claim, or reimbursement determination.

Professional, Coding & Reimbursement Disclaimer

This material is for general professional, operational and educational purposes only and is not medical, legal, regulatory, coding, billing, reimbursement, financial, payer-specific or contractual advice. Coverage requirements, utilization-management criteria, code sets, NCCI/MUE edits, payment methodologies, fee schedules, payer policies and contracts change. Organizations must verify current official sources, applicable payer contracts, CMS/MAC guidance, state requirements and licensed code sets before making operational, coding or reimbursement decisions. No authorization, payment, reimbursement, financial result or compliance outcome is guaranteed.